• ITM’s Chief Business Officer, Dr. Sebastian Marx, who also serves on the Executive Board, will resign on July 20, 2025, after almost 20 years with the company.
  • Roger Estafanos, the current U.S. General Manager and Executive Vice President, will be promoted to Executive Vice President, Global Head of Radiopharmaceuticals.
  • Alexander Pironi, currently Senior Vice President, will be appointed Executive Vice President, Global Head of Radioisotopes.
  • The new leadership structure reflects ITM’s strategic priority to boost growth in its radiopharmaceutical and radioisotope divisions.


Garching / Munich, Germany, March 13, 2025 – ITM, a prominent radiopharmaceutical biotech firm, has announced changes to its commercial leadership team. Dr. Sebastian Marx, Chief Business Officer and a member of ITM’s Executive Board, will step down on July 20, 2025, leaving the company after serving on the Executive Board since 2022 and being an employee since 2008. He has contributed nearly two decades of leadership to developing ITM’s business.

Effective April 1, Roger Estafanos, the current U.S. General Manager, and Alexander Pironi, the current Senior Vice President of Commercial Strategy and Services, will take on leadership roles overseeing ITM’s distinct radiopharmaceutical and medical radioisotope businesses. Mr. Estafanos will become Executive Vice President, Global Head of Radiopharmaceuticals, and Mr. Pironi will be named Executive Vice President, Global Head of Radioisotopes. Both will initially report to Dr. Marx until his departure in July, after which they will report to ITM’s CEO, Dr. Andrew Cavey.

ITM’s commercial structure is in line with its strategy as a vertically integrated company. This structure is designed to support the global launch preparations for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11), ensure commercial readiness for pipeline candidates in earlier stages, and expand its medical radioisotope business. The company is rapidly advancing, diversifying its global radioisotope portfolio and progressing toward potential market registration of ITM-11, pending approval, after successful Phase 3 results. ITM intends to submit a U.S. New Drug Application (NDA) to the FDA in 2025. Additionally, ITM is enhancing its pipeline of targeted radiopharmaceuticals, utilizing unique beta- and alpha-emitting radioisotopes to target high-need cancer indications.

“The Supervisory and Executive Boards appreciate Sebastian’s significant contributions to ITM. He was crucial in shaping ITM into the company it is today, helping to establish and grow our commercial relationships with hospitals, research institutions, physicians, and pharmaceutical partners of all sizes,” stated Dr. Andrew Cavey, Chief Executive Officer of ITM. “As ITM continues to grow, we are refining our commercial strategy to support the expansion of both our medical radioisotope business and our targeted radiopharmaceutical pipeline. I am thrilled to welcome Roger and Alexander into these vital roles. They both bring extensive expertise and a strong track record that will be essential in advancing our commercial strategy. Their leadership comes at an exciting time, as we build on the positive Phase 3 data for ITM-11 and prepare for the next stages of development and commercialization.”

Roger Estafanos has served as U.S. General Manager of ITM since 2023, successfully establishing and expanding the company’s presence in the U.S. He was also among the first leaders of the U.S. division of Advanced Accelerator Applications (AAA), a Novartis company, and has 15 years of management consulting experience, providing strategic advice to pharmaceutical, biotech, medical, and diagnostic companies on product commercialization across various disease areas.

Alexander Pironi has been with ITM since 2016, holding various leadership positions in commercial strategy, sales, and services. He assumed his current role as Senior Vice President in 2022. He is a key leader in the company’s commercial radioisotope business and has been important in expanding ITM’s commercial capabilities and team. 

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, focuses on delivering a new generation of radiopharmaceutical therapeutics and diagnostics for difficult-to-treat tumors. Our goal is to meet the needs of cancer patients, clinicians, and our partners through excellence in development, production, and global supply. With the improvement of patient outcomes as our guiding principle, ITM is advancing a broad precision oncology pipeline, including several Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By utilizing our two decades of pioneering radiopharma expertise, central position in the industry, and established global network, ITM aims to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.

ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:

Attachment

“`